The multiple antigen peptide (MAP} approach is an elfective method to chemically synthesize and deliver multiple T-cell and 8-cell epitopes as the constituents of a single immunogen. Here we report on the design, chemical synthesis, and immunogenicity of three PIDsmodium falcipamm MAP vaccines that incorporated antigenic epitopes from the sporozoite, liver, and blood stages of the life cycle. Antibody and cellular responses were determined in three inbred (C5781)6, BALB/c, and AJJ) strains, one congenic (HLA-Al on the CS7BU6 background) strain, and one outbred strain (CD!} of mice. All three MAPs were immunogenic and induced both antibody and cellular responses, albeit in a somewhat genetically restricted manner. Antibodies against MAP-1, MAP-2, and MAP-3 had an antiparasite effect that was also dependent on the mouse major histocompatibility complex background. Anti-MAP-1 (CSP-based} antibodies blocked the invasion of HepG2 liver cells by P.falciparum sporozoites (highest, 95.16% in HLA-Al CS781)6; lowest, ll.21% in BALD/c). Furthermore, antibodies generated following immunizations with the MAP-2 (Pf'CSP, PfLSA-1, PfMSP-1 41 , and PfMSP-3h} and MAP-3 (PfRAP-1, PfRAP-2, PfSERA, and PfMSP-1 41 } vaccines were able to reduce the growth of blood stage parasites in erythrocyte cultures to various degrees. Thus, MAP-based vaccines remain a viable option to induce effective antibody and cellular responses. These results warrant further development and preclinical and clinical testing of the next generation of candidate MAP vaccines that are based on the conserved protective epitopes from PIDsmodium antigens that are widely recognized by populations of divergent HLA types from around the world.
protection against clinical malaria in a placebo-controlled clinical trial that involved 5-to 17-month-old children in Kenya and Tanzania (3) . The limited suc{;ess of recombinant vaccines has led to a surge in interest to produce and test whole attenuated parasite-based vaccines against malaria, most of which are based on live attenuated Plasmodium fa/ciparum sporozoites (24, 59) . Nonetheless, the whole-parasite-based vaccination approach presents unique challenges in terms of safety, residual virulence, and the potential for reversion in virulence, mode of delivery, and difficulties associated with sufficient production for en masse vaccination. Thus, given the limited amount of clinical immunity conferred by the recombinantprotein-based vaccines and the perceived hurdles with the whole-parasite-based vaccines, it is imperative that malaria researchers continue to apply alternative options to develop and test candidate malaria vaccines.
The complex multistage life cycle of malaria parasites presents unique challenges for vaccine development. Immunity against malaria parasites is stage dependent and species dependent. Many malaria researchers believe that a single-antigen vaccine representing only one stage of the life cycle will not be sufficient and that a multiantigen, multistage vaccine that targets different stages of parasite development is necessary to induce effective immunity. Based on these assumptions, it is reasonable to argue that separate malaria vaccines may be needed to target the different parasite developmental stages and also multiple Plasmodium species that may be prevalent in a given area. In this context, a synthetic-peptide-based ap- . WORK UNIT NUMBER
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proach where multiple protective epitopes representing different stages of the life cycle, possibly from more than one Plasmodium species, are assembled in a vaccine construct appears to be an attractive approach for malaria vaccine development. The first peptide-based malaria vaccine was based on the repeat sequences of P.falciparum that underwent clinical testing in 1987 (21) . Since then, a number of synthetic peptide vaccines have been produced for both murine (P. berghei and P. yoe/ii) and human (P. falciparum and P. vivar) malarias and tested for immunogenicity (1, 31, 39, 61) or immunogenicity and efficacy (32, 52, 56) . However, in spite of the early momentum, several theoretical considerations and technological hurdles have slowed the progress of this vaccine development approach. Some of the perceived major arguments against the peptide-based vaccine approach include their short linear nature that prohibited the inclusion of multiple protective B-cell and T -cell epitopes in the same construct and the presumed inability to create the Cys-Cys disulfide bonds in conformationdependent epitopes. However, recent studies suggest that protein domains that mimic the native protein structure can be created in chemically synthesized peptide constructs that include conformationally correct Cys-Cys bonds to create immunologically active molecules (7, 48, 49) . ln addition, recently it has been suggested that large-scale and costeffective synthesis of peptide-based vaccines is possible (8) .
Currently, a reasonably large database of unique B-cell and T-cell epitopes from Plasmodium proteins, including those from human P. falciparum and P. vivax malarias, has become available. By conducting a comprehensive meta-analysis of available data for Plasmodium immune epitopes, Vaughan et a!. have identified more than 5,000 unique B-cell and T -cell epitopes for malaria parasites (60) . Several of the P.falciparum and P. vivax epitopes were identified in extensive field studies conducted over the last 2 decades (12, 23, 35, 57) and by computer-based predictions of immune epitopes by analysis of genomic and proteomic databases; some of these predictions were validated in HLA-peptide binding studies and in vitro immunological studies (4, (11) (12) (13) 29) . In this communication, we report the design, synthesis, and immunogenicity studies of three multiple antigen peptide (MAP)-based vaccines for P. falciparum malaria. These MAP vaccines were based on immunodominant B-cell and T-cell epitopes from the major malaria vaccine candidates, circumsporozoite protein (CSP), liver stage antigen 1 (LSA-1), merozoite surface protein 1 (MSP-1) and MSP-3, serine repeat antigen (SERA), and rhoptry-associated protein 1 (RAP-1) and RAP-2, representing the sporozoite, liver, and asexual blood stages of P.falciparum parasites. The synthesis of MAP vaccines was based on a novel technology developed by our group (6, 27) . We are presenting data demonstrating the immunogcnicity of these P. falciparum MAP vaccines in three inbred mouse strains (C57BL/6, BALB/c, and A/J), one congenic mouse strain (C57BU6 strain expressing the HLA-A2 molecule), and one outbred mouse strain (CD1). Th~.: HLA-A2 transgenic mice were included in these studies to facilitate the determination of the immunogenicity of a CSP-based peptide in MAP-1 that was recognized by supertypes HLA-A *0202 and HLA-A*6802 (12). lNFECI'. lMML'N.
MATERIALS AND JI.U:THODS
MAP synthesis and purification. TI1e tetrapeptide MAPs used in this study were synthesized hy using a patented technology dt'veloped at CBER. FDA, that allows the assembly of up to four epitopes as one molc~'Uic (6) . The individual malarial epitopes included in the MAP constructs were ha..ed on one or more of the following criteria: (i) identification as an immunodominam T-or B-c.:cll epitope in field studies, (ii) evidence for neutralizing antibodi<!s that block th<! invasion of liver cells by sporozoites or merozoite entry into erythroc-ytes, and (iii) reported function as a parasite ligand fadlitating the merozoite invasion of erythrocytes.
The MAP technology utilizes a pcptidyl core of three radially branched lysine residues onto which the malarial antigen sequences of interest were built using standard solid-phaw chemi~try. The lysine core is immunologically inert and generally accounts for less than 5% of the total molecular weight. The core template and the individual pe.ptides were synthe~ized at a 0.1-to 0.25-mm synthesis scale on an Applied Biosystems model 433A peptide synthesizer with 9-fluorenylmethoxycarbonyl chemistry mediated by 2-[1-H-henzotriazole-1-yl]-1.13.3-tetramethyluronium hexafluorophosphate/1-hydroxyhenzotriazole activation. Amino acids were purchased from Applied Biosystems and Anaspec (San Jose, CA). One millimole of each amino acid wa~ u.~ed for single coupling. The following side chain-protecting groups were used: Lys(Boc}, Ser(tBu). Glu(OtBu), His(trt), Asp(OtBu), Asn(Trt}, Arg(Pbf}. Gln(Trt), Trp(Boc). and C.)'S(Trt). Following final deprotection of the N·terminal amino acid hy piperidine, peptidcs were cleaved for approximately 3 to 3.5 h with a co.:k!ail containing trifluoroaretic acid (TFA), water. triisopropylsilane, and phenol (95: 1.25:15:2.25) and 250 mg dithiothreitol per 10 ml of cocktail. Following cleavage. peptides were precipitated and washed with methyl ten-butyl ether. Peptid<! pellets were resuspended in 0.1% TFA or 5 to 10% acetic acid and either subjected immediately to reverse phase high-perfonuan,·e li4uid chromatography (RP-HPLC) purification or lyophilized for long-tenu storage following semiprep purification of the crude mixture.
The peptides were purified by RP-HPLC using a Waters DeltaPak C 18 column (19 mm hy 300 mm, !5-IJ.m particle size, JOIJ-A pore size) and a linear gradient of0.1% TFA/water and 0.1% TFNacetonitrilc. Following purification, the acetonitrile wa~ removed hy low-stream nitrogen, followed hy a rotary evaporator, and the pcptides were then lyophilized for long-term storage.
Mil!t' and immunization. Female 6-to 12-week-old wild-type C' .57BIJ6 mice, C57BU6 mice expressing the human HLA-A2 Lransgent' (HLA-A2), and BALB/c, NJ, and outbred CD! mke were used in this study. The MAP vaccines were reconstituted in appropriate solvents. Groups of six mice each were immu· nized by three subcutaneous injections delivered at 4-week intervals. The vaccine formulation consisted of 20 ILg of tetraepitope MAP in I 00 ILl phosphatehutlered saline (PBS) emulsified in 100 ILl Montanide !SA 51 as an adjuvant. The control groups of mice received a similar volume of adjuvant in l'BS only. Blood sample.~ were drawn 2 days prior to each immunization and at 2 weeks after the last immunization. Serum samples from six mice per group were pooled and used in all serological assays. All of the experimental animals were housed, fed. and used in accordance with guidelines set forth in the National Institutes of Health manual Guide for the C'.arc and Use of Laboratory Animals. The Center for Biologics Evaluation and Research Animal Care and Use C.ommittce approved the an irnal study protocol. lmmuno10J!ical assays. (i) EUSA. Peptide-spedfic total lg.G levels were assayed in the sera of MAP-immunized and control immunized mice by enzyme linked immunosorbent assay (ELISA). Briefly. flat-bottom lmmulon !I ELTSA plates (Dynatech Laboratories) were coated overnight ar 4"C with 50 ILl of a 1-IJ.g/ml solution of either MAP or individual peptides or recombinant Pf(.'SP (rP!CSP) expressed in E!cherichia coli in PBS, pH 7.4. The well~ were hlocked hy incubation with 5% bovine serum albumin (BSA} in PBST (PBS containing 0.05% Tween 20) at 37"C for I h. Fifty-microliter volumes of 2-fold serial dilutions of the test sera or a control se rum in 1% BSA-PBST were added to the wells and incubated for (i) min at 37"C. The wells were washed thoroughly after incubation and then incubated with an alkaline phosphatase conjugate for 1 h. This was followed by development of the plate using phosphatase substrate tahlets (Sigma Aldrich Co.) and mea~urement of the optical density at 405 nm using an ELISA reader.
(ii) IIF. Indirect immunofluorescence: (IJF) was performed against the sporozoite and j ntrac:rythr<x.)'lic stage~ of P. fu/cipurum para~ itt's coating 12·well slides using the sera obtained at 2 weeks afte r the third immunization. Parasites were in~'Ubated with serial dilutions of sera and incubated in a moist chamber at 37"C. After I h of incubation, unbound material was removed hy washing and Alexa Flour 488 goat anti-mouse IgG (Invitroge n Co rporation) was added to the cells. Following washings, slides were mounted using VECTASHIELD mounting me-dium for fluorescence (Vector Laboratori~s Inc.) and evaluated using a fluores-.:ence microscope. Slides processed with preimmune mouse: sera were used as controls.
In vitro infection of HC-04 human hcpatocytes and IIF. The sera from the mice immunized with MAP-2 were also tested for the ability to react with P.
falciparum liver stage parasites. The HC-04 human hepatocyte cell line is known to support the development of P . .falciparum liver forms ( 44) . HC-04 cells ( 40,0001well) were sc~ded into Lab-Tek dght-chan1bered plastic slides precoated with ECL (elastin-collagen-laminin) 1 day before infection. Purified P. falcipamm sporozoitcs of the 307 strain (50,000 in 50 JJ.l Oulbccco's modified Eagle's medium [DMEM]-nutrient mixture F-12 containing 10% fetal bovine serum [FBS] and 1 x penicillin-streptomycin) were added to each wdl containing HC-04 cells. Slides were incubated for 3 h at 37"C in 5% C0 2 , after which the P. falciparum sporozoite suspension was aspirated from each well and each well was washed thre~ times with complete OMEM-nutrient mixture F-12. P.falciparum sporozoite-infected HC-04 cells were maintained at 37"C in 5% C0 2 for 3 days with a daily change of medium. AI day 3 postinfection with sporozoite.~. slides were treated with chilled methanol for 15 min at room temperature. 1l1e fixed parasites were washed for 5 min each at room temperature on a rocker platform with three changes of I X PBS. The polyclonal antibody raised against MAP-2 was usc:d as th~ primary antibody. A 100-JJ.l aliquot of anti-MAP-2 antibody at a 1:50 dilution in PBS was added to each well of the Lab-Tek slide containing fixed liver stage parasites developing in HC-04 cells and incubated at 37"C for 1 h.
After three washings, 5 min each at room temperature, a IO<l-JJ.I aliquot of goat anti-mouse Alexa Fluor 488 (Invitrogen Corporation) at a 1:200 dilution in PBS containing a 1:1,000 dilution of 4',6-diamidino-2-phenylindole (OAPI) from a 2-rng/ml stock and 0.001% Evans blue, was added to each well of the Lab-Tck slide. The slides were incubated for 1 h at 37"C, and then the wells were washed three times with PDS and the slide was mounted with a coverslip using VEC!'ASHIELD mounting medium. The slide was observed under a fluorescence microscope using x400 magnification using filters for green (for Alexa 488), red (Evans blue), and blue (OAPI). Images w~re captured from the same field viewed with these three filters and superimposed on one another to get the final multicolored images.
(iii) Enzyme-linked immuno~pot assay (EUSPOT) a•say for detection of gamma interferon (IFN-y)-a nd ioter!eukin-4 (IL-4)-secretiog cells. Freshly isolated spleen cells taken from the mice on day 14 after immunization were used to detect IFN-y-and IL-4-secrcting cells. Plates were coated with either anti-IFN-y or anti-llrl (BO Bioscience.~) capture antibody in PBS and kept at 4°C. 1l1~ following rooming, plates were blocked with 10% FDS-RPMI1640 medium for 2 h. Freshly isolated spleen cells in complete medium (2 x 10~/100 JJ.l) were added to each well along with 100 J!l of antigen (MAP or individual peptides) and cultured for 36 h at 37"C. '!11e plates were washed with PBST, and biotinylated detection antibody was added for 2 h of incubation at room temperature. This was followed by washing and addition of streptavidin-horseradish peroxidase enzyme conjugate for 1 h. After repeated washing, the spots were revealed with DAB reagent (KPL Inc.) and enumerated using an AID EliSpot Reader System (Cell Technology Inc.). I.FN-y and llrl ex vivo responses were scored as the mean :!: the standard deviation in triplicat~ wells. The results were expressed as the number of IFN-y or 1L-4 spot-forming cells (SFC) per 10 6 splcnO<.-ytcs. Biologicol assays. (i) In vitro inhibition ofspomzolte invasion (lSI) assay. The sera from the mice immunized with MAP-I were tested for the ability to inhibit sporozoite invasion in HepG2 (human hepatoma) cells. Th~ assay was pertom1ed as described by Shi et al. ( 46) . Briefly, HepG2 cells were collected. washed, and resuspended in complete minimal essential medium and subsequently plated at a density of 50,000 cellsi0.3 ml in ECifcoated Lab-Tek glass slides and incubated for 2 days at 37"C in a C0 2 int·ubator. The following day, the medium was removed and dilferent dilutions of anti-MAP serum or the anti-CSP repeat monoclonal antibody (MAb) NFS! (positive control) were added per well (in triplicate). This was immediately followed by the addition of 20,000 sporozoites in 50"'' of m~dium to each well. P . .falciparum (strain NF54) sporozoites were obtained by dissection of the salivary glands of Anopheles stephcnsi mosquitoes as described by Ozaki et al. ( 38) . The sporozoites were allowed to invade liver cells for 3 h, and then the cells were washed with PBS (pH 7.4). Subsequently, the cells were fixed with cold methanol. Sporowites were visualized by in1munostaining by using NFS1 as the primary antibody and anti-mouse IgG-peroxidase conjugate. Diaminobenzidine wa~ used as the substrate. The slides were mowlled with Paramount, and intracellular sporozoites were identified ami cow1ted. Percent inhibition of invasion was calculated as follows: % inhibition = 100 x (1 -(mean number of P. falciparwn sporo1.oitcs invading HepG2 cells in test sample)/( mean number of P. falciparum sporozoites invading HepG2 cells in control samples)).
(II) Merozoite growth inhibiliun assay (GIA). TI>e sera from the mice immunized with MAl' -2 and MAP-3 were tested for the ability to inhibit merowite MAP VACCINES AGAINST P. FALCIPARUM MALARIA 4615
growth by GIA as previously described (20) . Briefly, P. falciparum (clone 307, FVO, and Camp strains) cultures were prepared in 48-well plates and kept in suspension culture angled on a rotator platform in heat-sealed plastic bags. Synchronized cultures adjusted to 0.2% late ring stages were mixed with sera (1 :10 dilution) raised against the MAP vaccine or control serum to a final hematocrit of 4%. The: cultures were harvo:sted after 48 h, stained with Hoc:chst dye 33342, and analyzed by flow L)'tometry. The fluorescenL-e signal was determined for a minimum of 40,000 erythro<-ytes gated on forward scatter. TI1e percent inhibition was calculated from the mean parasitemia of triplicate test and control wells as 100 x [(control -test)/control].
RESULTS
Design and characterization of MAPs. MAP-1 included multiple epitopes from PfCSP, a major protein on the malaria sporozoite surface. CS proteins from different Plasmodium spp. have a few structural features in common, including a signal peptide, a variable central domain (composed of tandem repeats of amino acid sequences and two highly conserved ~egions), and a C-tcrminal hydrophobic sequence (30) . In P.
falciparum, the central region is composed of major repeat units of NANP and a minor repeat unit of NVDP (NANP X 37 and NVD P X 2 for the 3D7 strain of parasite). CSP repeats from the human and murine Plasmodium species are recognized as both B-cell and T-cell epitopes (18, 62) . Antibodies against the repeal region can block sporozoites from entering cultured hepatocytes (2, 62, 63) . These antibodies can also passively protect mice from sporozoite challenge in murine malarias (14, 40) . Although the earliest immunological and vaccination studies were predominantly focused on the NANP repeat units, several additional B-ccll and T -cell cpitopcs have been identified on PfCSP (5, 18, 19) .
The peptide S-7 (amino acid sequence DPNNANPNVDPN ANPNV) was chosen from the 5' part of the minor repeat region that was identified as a CD4+ T-cell epitope from T-cell clones derived from a P.falciparum sporozoite-immunized volunteer (33) . The peptide S-8 (amino acid sequence PNANPN ANPNANPNANP) was chosen from the region of tandem repeats of NANP that contain an immunodominant B-cell epitope (33, 34) . Major constraints to the development of subunit-based malaria vaccines arc the Hl.A-restricted immune responses and antigenic polymorphism prevalent in the major malaria vaccine candidates (13, 23, 51. 54) . Likewise, some of the immunodominant T-cell epitopes recognized by individuals in areas where malaria is endemic are either HLA dependent and/or located in the highly polymorphic regions of the molecule (12, 26, 42, 43, 55) . To provide a wider immune responsiveness for the MAP-1 vaccine, epitopes S-9 and S-10 were included. Peptide S-9, located in the C-1erminal hydrophobic polymorphic domain (amino acid sequence SVFNVV NSSIGLIMVLSFLFLN), has been ident.ified as both a CD4+ T-cell and a CD8+ T-cell epitope, while peptide S-10, from the conserved N-terminal signal peptide region (amino acid sequence IUiVSSFLFV), was identified based on its binding with supertypes HLA-A *0202 and Hl.A-A *6802 and demonstrated cytotoxic T-lymphocyte (CfL) activity in peripheral blood mononuclear cells from an irradiated-sporozoite-immunized volunteer (12) . ously identified B-cell epitopes from PfCSP that arc outside the repeat region, sequences KPKHKKLKQPGDGNP (S-lla) and ENANANNAV (S-llb). Epitope S-lla was recognized by sera from individuals living in Gabon, where malaria is endemic (9). Epitope S-llb was recognized more frequently by sera from Brazil and Papua New Guinea than by those from Kenya ( 47) . Epitope S-12 is a combination of two strong T -cell epitopes from LSA-1. The LSA-J peptide is located at the junction of the last repeat unit and the next seven residues from the nonrepetitive region (amino acid sequence ERRAK EKLQEQQRDLEQRKADTKK), while Ls6 is from the Cterminal region of LSA-1 (amino acid sequence KPIVQYD NF). Both of these peptides have proven T-cell-stimulatory activity (15, 28) . Peptide S-13 (amino acid sequence GISYYE KVIAKYKDDLE) was chosen from block 15-16, the dimorphic region of P. falciparum MSP-1 42 . In a study in western Kenya, 55% of the individuals tested had proliferative responses to peptide S-13 (57) . Finally, the fourth peptide, S-14 (amino acid sequence AKEASSYDYILGWEFGGGVPEHK KEEN), for MAP-2 was selected from MSP-3b. This 27-amino-acid peptide from MSP-3b was identified as the target for antibody-dependent cellular inhibition (ADCI) in the sera from African adults who had clinical immunity to malaria. Affinity-purified antibodies against MSP-3b peptides are effective in killing P. falciparum parasites in vitro through an ADCI mechanism that required the presence of monoc'}'tes (35). (41) . The fourth epitope is again a red-cell-binding domain from the 33-kDa processing fragment of MSP-1 (amino acid sequence DVIYLKPLAGVYRSLKKQLE) and has been shown to be involved in a receptor ligand-type interaction between merozoites and red blood cells (58) . Figure IC shows the locations and amino acid sequences of MAP-3 peptides.
Characterization of MAPs was performed by matrix-assisted laser desorption ionization-time of flight mass spectrometry and amino acid analysis (data not shown). In addition to MAPs, individual peptides were also synthesized and characterized for use in immunological assays. Fig. 2A) .
When rPfCSP was used as a coating antigen, the responses were again highest in HLA-A2 mice (84,302:!: 6,191), followed by C57BU6 mice (76,304 :!: 2,182) and BALB/c mice (204 :!: 28), and negligible in A/J mice ( Fig. 2A) . The response in CD1 mice was 60-fold lower than in HLA-A2 mice . These results show that the combination epitopes contained within MAP-2 wae able to induce relatively high-level, wide-ranging immune responses in diverse major histocompatibility complex (MHC) types (Fig. 2B) .
Although MAP-2 contained a strong B-cell epitope from PfCSP (peptide S-1 l ), sera from all four strains of mice failed to react when rPfCSP was used as a coating antigen (data not shown). We further tested the reactivity of sera from mice immunized with MAP-2 with individual peptides. The sera from the four strains of mice also failed to recognize the S-11 peptide. S-12 is aT-cell epitope from LSA-1. When S-12 was used as a coating antigen, there was a moderate but consistent reactivity with sera from NJ (372 ::!:: 155), BALB/c ( 401 ::!:: 90), and CD1 mice (447::!:: 133). However, sera from C57BU6 mice failed to recognize the S-12 peptide. These results strongly indicate that peptide sequence S-12 also contains a previously unrecognized, novel B-cell epitope. Peptide S-13, a known T-cell epitope, also showed a low level of recognition in NJ mice (154 ::!:: 63) which was -12-fold higher than the sera from Montanide ISA 51 control mice (13 ::!:: 1). Peptide S-14 had both aT-and a B-cell epitope from MSP-3. Among the four epitopes from MAP-2, S-14 was maximally recognized and sera from all four strains of mice reacted with the S-14 peptide. The ELISA IgG titers were 21,222 ::!:: 2,525 (NJ mice), 18,759 ::!:: 4,933 (BALB/c mice), 10,177 ::!:: 3,270 (C57BU6 mice), and 13,887::!:: 9,445 (CD1 mice) (Fig. 2B) . There was no detectable reactivity with the sera of mice immunized with Montanide ISA 51 only (data not shown).
(c) Responses to MAP-3. MAP-3 contains sequences only from blood stage antigens that include epitopes from PfRAP-1 and PfRAP-2 and two epitopes from red-cell-binding domains (SERA and MSP-1). This vaccine induced extremely high-level antibody responses in all of the mouse strains tested when MAP-3 was used as a coating antigen. The highest titers were found in NJ (309,801 ::!:: 18,765) and BALB/c (245,734 ::!:: 30,307) mice, followed by CD1 mice (73,433 ::!:: 33,807); the lowest (but still substantial) responses were observed in C57BU6 mice (37,995 ::!:: 5,018) (Fig. 2C) .
IgG responses to individual peptides were also evaluated. Although peptide S-15 is a potent B-cell epitope from RAP-1, sera from mice immunized with MAP-3 failed to react with the S-15 peptide. The sera from all four strains of mice reacted strongly with the S-16 peptide, which possesses sequences representing both T-and B-cell epitopes from RAP-1 and RAP-2. 2,792 in CDI mice and 13,880 ::!:: 2,567 in C57BL!6 mice). The S-18 peptide, a red blood cell-binding epitopc from MSP-1, was nonimmunogenic in all groups of immunized mice (Fig. 2C) .
(ii) Antibody responses measured by IU'. We next wanted to know if antibodies against MAP vaccines react with native antigens expressed on the parasite during their respective stages of the life cycle. To accomplish this, we evaluated the reactivity of pooled sera from mice immunized with MAP vaccines with sporozoite stage, liver stage, or asexual blood stage parasites by IIF. Sera from MAP-1 (four epitopes from CSP)-immunized mice were tested against P.falciparum sporozoites. MAP-1 vaccine induced extremely high titers of antibodies against CSP present on the sporozoite surface. The sera from HLA-A2 mice reacted with the sporozoites with an endpoint titer of 409,600. This was followed by the reactivity of sera from BALB/c (102, 400) and C57BL/6 (25, 600) mice. The sera from CD1 and NJ mice also recognized the sporozoites, but their endpoint titers were lower (800 for CD1 mice and 100 for NJ mice) ( Table 1) .
Since the MAP-2 vaccine construct contains a peptide based on the LSA-1 sequence, we determined the reactivity of sera from the mice immunized with MAP-2 with the liver stage malaria parasites. P. falciparum sporozoites were allowed to develop to the liver stage form in human hepatoc.,yte cell line HC-04 for 3 days. When tested at a I :50 dilution, sera from immunized BALB/c, C57BU6, and CD1 mice recognized the liver stage parasite (Fig. 3B, C, and D) ; the intensity of fluorescence of these sera was equivalent to the reactivity seen with a polyclonal mouse antibody generated by immunizing with a DNA plasmid containing the LSA-1 gene (A). The recognition of liver stage P. falciparum parasites by MAP-2-immunized mouse sera indicates that the LSA-1 epitope (peptide S-12) in the MAP-2 vaccine was able to generate antibodies that may be effective against liver stage parasites.
MAP-2 and MAP-3 contained epitopes from the asexual blood stages of the life cycle, and consequently, sera raised against the MAP-2 and MAP-3 vaccines were tested against the asexual blood stage P. falciparum parasites by IIF. MAP-2 vaccine induced various levels of antiparasite antibodies in the four strains of mice tested. The highest reciprocal endpoint titer was observed in NJ mice (1:1,600). The titer in BALB/c and C57BL/6 mice was 1:400, followed by 1:200 in CD1 mice ( Table 1 ). The sera from MAP-3-immunized mice also recog- nized the blood stage schizonts. The titer was highest in CDl mice (1:3,200), followed by BALB/c (1:1,600), NJ (1:800), and C57Bl)6 (1:400) mice ( Table 1 ). The antibody responses measured by ELISA and IIF showed that MAPs were generally highly immunogenic and they induced antibodies that specifically recognized the epitopes on the P. falciparum sporozoite, liver, or asexual blood stage of the life cycle.
(iii) Induction ofT -ceU responses. We also investigated whether the T -cell epitopes contained in the MAP vaccines were able to generate cell-mediated immunity by assessing the ability of the spleen cells to generate IFN-'Y and llA responses following immunization with MAP-1 or MAP-2 vaccine. Spleen cells were harvested from MAP-1-immunized HLA-A2, C57Bl)6, and BALB/c mice and MAP-2-immunized C57Bl)6 and BALB/c mice on day 14 after the third immunization and cultured for 36 h in the presence of MAP constructs or individual peptides.
The spleen cells from the three strains ofMAP-1-immunized mice were able to produce IFN-'Y and IL-4 after in vitro stimulation with MAP-1 (Fig. 4A) . The IFN-'Y responses were /10 6 splenocytes) mice, while 235 SFC/10 6 splenocytes were observed in BALB/c mice. While investigating the contributions of individual peptides, we found that peptide S-8, a NANP repeat and a known T-and B-cell epitope, was responsible for the induction of a large portion of the IFN--y-secreting cells by MAP-1 in HLA-A2 (341 SFC/10 6 splenocytes) and C57BU6 (275 SFC/10 6 splenoc.,-ytes) mice. The IFN--y responses induced following stimulation with the S-8 peptide in spleen cells from BALB/c mice were lower (80 spots/10 6 cells), suggesting that the cellular response induced by the S-8 peptide in the MAP-1 vaccine was under the regulation of MHC genes. The spleen cells also responded to the other three MAP-1 peptides, but the responses were significantly lower (Fig. 4A) . The IL-4 production by spleen cells followed the IFN--y production pattern, except at a lower level, when the cells were cultured in the presence of the MAP-1 construct. The responses were equivalent in HLA-A2 (195 SFC/10 6 splenocytes) and C57BL/6 (178 SFC/10 6 splenocytes) mice, followed by that of BALB/c (94 SFC/10 6 splenocytes) mice. We then evaluated IFN--y and IL-4 production in response to MAP-2 immunization in C57BL/6 and BALB/c mice. The spleen cells from both strains of mice induced IFN--y and IL-4 production when cultured in the presence of either the MAP-2 construct or individual peptides (Fig. 4B) . The responses of C57BL/6 mice were always stronger than those of BALB/c mice. The frequency of IFN--y-secreting spleen cells in C57BU6 mice (436 SFC/10 6 splenocytes) was highest in response to the S-14 peptide, which is an ADCI epitope from MSP-3. This epitope has been previously described as a T -cell epitope recognized by the majority of individuals in areas where malaria is endemic (36, 50) . This was followed by response to the MAP-2 construct (290 SFC/10"' splenocytes) and the S-11 peptide (150 SFC/10 6 splenocytes), which is a B-cell epitope from PfCSP. The responses to the S-12 (77 SFC/10(' splenocytes) and S-13 (76 SFC/10 6 splenocytes) constructs, though lower, were also significant. In BALB/c mice, the highest IFN--y responses were observed in response to the S-13 peptide (205 SFC/10 6 splenoc-ytes), which is a known T-cell epitope from MSP-1. This was again followed by 112 SFC/10 6 splenocytes in response to the MAP-2 construct and 70 SFC/ 10 6 splenocytes in response to the S-14 peptide. The responses to the S-11 and S-12 peptides were weaker (Fig. 4B) .
A~~--------------~----------------~--------------~
We also investigated IL-4 responses in MAP-2-immunized mice. The IL-4 responses also followed the pattern of IFN--y responses, but at a lower level. In C57BU6 mice, the responses to the S-14 peptide were the strongest (186 SFC/10 6 splenocytes). The IL-4 production was equivalent in response to MAP-2 or the individual peptide S-11, S-12, or S-13. In BALB/c mice, the IL-4 (130 SFC/10 6 splenocytes) responses to the S-13 peptide, which is aT-cell epitope from MSP-1, were the strongest. The responses to the MAP-2 construct and individual peptides S-11, S-12, and S-14 were comparable. Overall, while MAP vaccines and their component peptides were able to generally induce high levels of cellular responses in mice of disparate MHC types, in some instances, these responses were under the regulation of the host genetic background. (Table 2 ). Pooled sera from immunized HLA-A2 mice showed the highest level of inhibition (95.16%) of sporozoite invasion, followed by sera from C57BU6 (88.72% ) and CDl (66.08%) mice. The lSI effect observed in sera from immunized HLA-A2 mice was almost equivalent to that of an anti-CSP MAb (NFS1) used as a positive control. The ability of the antibodies generated against the MAP-1 construct to inhibit sporozoite invasion in vitro shows that the antibodies are biologically active and effective in reducing the invasion of liver cells by sporozoites.
(li) Merozoite GIA. Since both MAP-2 and MAP-3 contained epitopes from the asexual blood stage of P. falciparum , antibodies generated against these MAPs were tested to determine if they could affect the growth of blood stage parasites in erythrocytes. GIA was performed with the P. falciporum 3D7, FVO, and Camp strains in suspension cultures. MAP-2 contained epitopes from two blood stage antigens, PfMSP-1 42 and PfMSP-3b ( Camp, 35% ); sera from C57BL/6 and NJ mice were not effective in the GIA. In MAP-3, all four epitopes were from antigens present in the blood stage of the life cycle (Fig. 1C) . Sera from immunized C57BL/6 mice demonstrated the highest level of GIA activity against all three P. falciparum strains tested (3D7, 54%; FVO, 73%; Camp, 62% ), while the lowest GIA activity was seen in CDl mice (3D7, 11 %; FVO, 24%; Camp, 29%) (Fig. 5) . Thus, the generation of growth-inhibitory antibodies by MAP vaccines appeared to be dependent on the mouse MHC background. We also noted some variations in the level of GIA activity in immunized sera when they were tested against different P. falciparum strains, suggesting that sequence diversity in antigenic epitopes incorporated in the MAP constructs may influence the protective efficac...")' of MAP vaccine.
mSCUSSION
In this study, we have revisited the concept of a multi antigen, multiepitope vaccine by assembling several immunodominant B-cell and T-cell epitopes from the antigens from the sporozoite, liver, and asexual blood stages of P. falciparum as synthetic MAP vaccines. Previously, we have reported on the design, novel methodology for synthesis, and immunogenicity studies of three MAP vaccines in mice (27) . Now we report on the next generation of three MAP vaccines that are based on the better-characterized effective T-cell and B-cell epitopes from P. falciparum that are available in the literature, and we demonstrate their antibody and cellular responses in different MHC haplotype mice.
MAP-1 was based on the antigenic sites from the P. falciparum CSP that contained a total of four epitopes (Fig.   lA) . Following three immunizations, the strongest anti-MAP-! ELISA IgG responses were observed in mice with the C57BU6 background (in both the HLA-A2 transgene and the wild-type genotype), while weaker responses were seen in BALB/c and CDl mice and the vaccine was almost nonimmunogenic in NJ mice (Fig. 2A) . Since the NANP repeat sequence was the only known B-cell epitope present in MAP-1, we think that the majority of anti-MAP-1 and anti-PfCSP ELISA IgG responses detected were directed against this par-MAP VACCINES AGAINST P. FALCIPARUM MALARIA 4621 ticular epilope. Our finding that the strongest ELISA response was generated in the C57BL/6 background is in agreement with an earlier report demonstrating that the antibody response to the NANP epitope was under MHC regulation and mapped to the l-Ab gene product (17) . While (NANP)n ~2-mer has been shown to contain the B-cell epitope, (NANP)n ~16-mer is essential for optimal T-cell activity (17) . Since MAP-1 contained only four repeats of NANP, the strong anti-CSP ELISA IgG response observed in this study ( Fig. 2A) could be attributed to T -cell help provided by the other immunodominant CD4 + T-cell epitopes in this vaccine. Alternatively, it is possible that fewer repeat units of NANP arc needed for effective T-cell function when presented as macromolecules such as MAP. The inability of peptide S-8 to recognize anti-NANP antibodies can be explained by the fact that >40 NANP repeats are needed to serve as an effective ELISA coating antigen (10) . Immunizations with the MAP-1 vaccine also induced antibodies against the native sporozoite surface antigens as measured by IIF. The highest antibody levels were observed in C57BU6 HLA-A2 mice (mean endpoint titer, 409,600), while the lowest antibody levels were seen in A/J mice (mean endpoint titer, 100). MAP-1 immunization-induced antibodies were also highly effective in preventing the invasion of liver cells by P. falciparum sporozoites. Again, the strongest sporozoite invasion-inhibitory effect was seen in the sera from C57BL/6 HLA-A2 mice (95.16% invasion inhibition), and in fact these antibodies were almost equivalent to anti-CSP MAb NFSl (positive control) in their inhibitory effect. Although the generation of sporozoite invasion-inhibitory antibodies was somewhat dependent on the MHC-background, some inhibitory effect was present in sera from all of the mouse strains tested (Table 2) . MAP-1 vaccine also induced effective cellular responses, as measured by the frequency of IFN-'Y-and IL-4-producing splenocytes. In a recall ELISPOT assay following stimulation with peptide S-8, the highest frequencies of IFN-'Y·producing spleen cells were observed in C57BU6 HLA-A2 and wild-type C57B1)6 mice. IFN-'Y-producing cells, albeit at a lower level, were also observed with the other three peptides containing T-cell epitopes. Generally lower frequencies of IL-4-producing cells were seen in all of the mouse strains when splee n cells were stimulated against the four individual peptides. JFN-'Y is known to play a critical role in immunity against preerythrocytic-stage malaria (37) , and the fact that MAP-I immunizations induced a high frequency of IFN-'Y-producing T cells raises the prospect that in clinical studies, this vaccine might induce effective responses that target liver stage parasites.
The most interesting aspect of this study was that, contrary to our expectation, the presence of HLA-A2 molecules in the C57B1)6 background facilitated the generation of higher anti-MAP-! antibody levels (1.3-fold by ELISA and 16-fold by IIF) and slightly greater lSI activity (P > 0.027) than their wildtype C57BL/6 counterparts. Surprisingly, expression of the HLA-A2 product did not influence either overall MAP-1-specill.c or peptide S-10-specitic cellular responses, as measured by the frequency of IFN-'Y·producing spleen cells by ELISPOT assay. How the presence of the HLA-A2 product influenced the magnitude and biological activity of anti-MAP-1 antibodies in C57BL/6 mice is not clear. One possibility is that the cyto-kines synthesized by CD8 • T cells that were generated following the interactions between Hl.A-A2 and the peptide S-8 complex had influenced the quality and quantity of antibodies synthesized by primed B cells. However, additional studies are needed to address this question.
MAP-2, which included B-cell and T-cell epitopes from CSP and LSA-1 (pre-l;!rythrm:ytic stage), and MSP-1 and MSP-3 (blood stage antigens) induced high ELISA IgG titers in all four strains of mice tested. Among the four epitopes that constituted MAP-2, no antibody response was detected against peptide S-11, which is composed of two B-cell epitopes from PfCSP. The first epitope (S-lla) is located at the NH 2 terminus to the repeat region and constitutes a part of the RI domain. This sequence was identified as a B-cell epitope in two independent studies in Africa (9, 47) but was found to be nonresponsive in C57BL/6 mice when delivered in complete Freund"s adjuvant (9) . The second epitope (S-llb) was first identified based on its reactivity with an anti-CSP MAb generated in BALB/c mice (53) and recognition by sera from individuals living in Papua New Guinea and Brazil ( 47) . Our studies suggest that while these B-ccll epitopes are individually recognized by some individuals living in areas where malaria is endemic, when presented as a combination epitope in a MAP vaccine, they arc not effective B-cell cpitopcs in mice. A moderate antibody response was detected in three out of four strains of mice against peptide S-12, a known T-ccll epitopc from LSA-1, suggesting the presence of a previously unidentified B-cell cpitopc within this sequence. In a study of children in Gabon, IFN--y secretion in response to the LSA-J and l.s6 epitopes was associated with resistance to reinfection in mild malaria but not in severe malaria (28) . The l.s6 epitopc of LSA-1 has been shown to generate CTL responses in Hl.A-B53-and Hl.A-B35-positive individuals (23), and CTL responses to it arc associated with protection against severe malaria in Hl.A-B53-rcstricted individuals in Gambia (22, 23) . Peptide S-14 was immunogenic in all four strains of mice and induced the strongest ELISA IgG responses among the four peptides that constituted MAP-2 (Fig. 2B) . Peptide S-14 is based on the well-characterized B-cell and T-ccll epitopes from MSP-3. This epitope is recognized by the predominantly L')'tophilic lgG1 and lgG3 subclasses of antibodies in sera from adults immune to malaria (35). Antibodies that were isolated by immunopurification of immune sera against this epitope are known to kill P. falciparum parasites in vitro through an ADCI mechanism that requires the presence of monocytcs (35). The most effective cellular responses measured following MAP-2 immunizations were also against peptide S-14, i.e., 436 IFN--ysecreting SFC/10 6 splenocytes in C57BL!6 mice. A lower level of response against peptide S-12 (aT-cell epitope from LSA1) was detected, i.e., 77 SFC/10 6 splenocytes. The most effective response was against peptide S-13 in BALB/c mice, which had 205 SFC/10 6 splcnoL')'tes. Anti-MAP-2 antibodies had no GIA activity.
MAP-3, composed of four antigens from the asexual blood stage of P. falciparum, was highly immunogenic in all of th mouse strains tested, with the highest titers achieved in NJ and BALB/c mice. It appears that most of this response was directed against peptide S-16, a major B-cell and T-cell epitope in RAP-1 and RAP-2. Peptide S-17, a red-cell-binding domain from SERA, induced high levels of antibodies in BALB/c and INFECT. lMMUN.
NJ mice and moderate levels in C57BL!6 and CD1 mice (Fig.  2C) . Anti-MAP-3 antibodies were also biologically relevant, with the strongest effect seen in the sera from C57BL/6 mice, a 54 to 73% reduction in the growth of different strains of blood stage P. falciparum parasites in erythrocyte cultures, while a lesser degree of GIA activity was demonstrated in sera from the other three strains of mice (Fig. 5) .
In summary, we have designed and constructed three novel MAP vaccines and determined their immunogenicity in four strains of mice of disparate MHC types. These MAP vaccines were able to induce effective antibody and cellular responses, although immune responses against the individual pep tides were generally MHC dependent. Sera from immunized C57BU6 mice also exhibited a high level of lSI activity (anti-MAP-1) and a moderate level of GIA activity (anti-MAP-3). These studies have allowed the identification of a set of immunogenic peptides that could be incorporated in the next iterations of l\.1AP constructs that may generate highly dl"cctivc antimalarial responses in populations of genetically diverse Hl.A types.
